APA (7th ed.) Citation

Bischoff, J., & Marmé, F. (2016). A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -. Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw365.52

Chicago Style (17th ed.) Citation

Bischoff, Joachim, and Frederik Marmé. "A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients with Her2-positive Metastatic Breast Cancer - E-Vita -." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw365.52.

MLA (9th ed.) Citation

Bischoff, Joachim, and Frederik Marmé. "A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients with Her2-positive Metastatic Breast Cancer - E-Vita -." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw365.52.